Patients receiving antitumor chemotherapy are at increased risk of developing nosocomial infections, and the antibacterial therapy of such infections is often monitored by bioassay. The effect of antitumor agents on seven bioassay procedures using strains of Sarcina, Klebsiella, Clostridium, Pseudomonas, Staphylococcus aureus, and S. epidermidis or Bacillus was evaluated. The minimum inhibitory concentrations of six antitumor drugs, cytarabine, dactinomycin, doxorubicin, 5-fluorouracil, methotrexate, and vinblastine, determined for each of the test organisms, showed that 5-fluorouracil, dactinomycin, and doxorubicin are used at blood levels sufficient to interfere with bioassay procedures. The other drugs have miniimum inhibitory concentrations as much as 100 times the expected blood levels. Antibiotic (gentamicin, kanamycin, cephalothin, and carbenicillin) recovery experiments in the presence of therapeutic levels of antitumor agents showed no in vitro inactivation of antibiotic. However, at low cephalothin concentrations (less than 20 ,ug/ml) in the presence of 5-fluorouracil, bioassay results were in error by as much as 100%. The data indicate that bioassay procedures for the determination of antibacterial drug levels may need to be modified for those patients receiving antitumor therapy with 5-fluorouracil, doxorubicin, or dactinomycin.
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Due to the increased risk and presence of infections, the management of patients receiving cancer chemotherapy frequently includes the use of antimicrobial agents. Bioassay of these antimicrobial agents is often used for monitoring serum drug levels to insure the adequacy of the desired antibacterial therapy or prevent possible toxicity. Such antibacterial drug bioassays depend on a linear, first-order reaction between the drug and the test reagent (bacteria). Therefore, drugs having an antibacterial effect when used in combination with other antimicrobial agents might interfere with or bias the results of such an assay.
Reports (3, 5, 8) The antibacterial action of the chemotherapeutic agents used in this study was determined independently for each of the test organisms. The MICs of these agents are shown in Table 1 and indicate almost complete resistance of the assay organisms to methotrexate, cytabarine, and vinblastine. 5-Fluorouracil was almost uniformly antibacterial at easily achievable blood drug levels, whereas dactinomycin and doxorubicin showed mixed MICs. Both staphylococci and S. lutea, C. perfringens, and possibly B. subtilis were susceptible to dactinomycin and doxorubin at achievable blood levels, whereas K. pneumonia and P. putida were rarely susceptible.
The question of whether the antineoplastic agents would react antagonistically or synergistically with antibiotics assayed with the above noted bacteria was examined by completing a bioassay experiment using the agents both in combination and individually. The results of these experiments are shown in Table 2 . Results are given for only one concentration of each of the agents used; however, other concentrations were also tested without a significant change in the results. The data shown in Table 2 represent the median of from four to eight experiments, and the percent control shows the relative size of inhibition zones obtained with drug combinations as compared with those of the antimicrobial agents used alone. The data suggest that there is no apparent effect of the combinations of the agents (i.e., no additive, synergistic, or antagonistic effects), except with the combination of 5-fluorouracil and cephalothin. The fact that the percent control is often other than 100 may reflect the additional dilution steps or ma- WRIGHT AND MATSEN ments. It would appear from the MICs that we might have expected more interferer.ce in the bioassay procedures, e.g., 5-fluorouracil interfering with gentamicin assayed on K. pneumoniae or S. aureus, than occurred when tested. Because at the concentrations of antitumor agent tested there was, in general, no inhibition of growth in the assay system, we questioned what drug levels would be necessary before we could reasonably expect to see some effect in these systems. Therefore, we decided to complete bioassays at several drug concentrations with antitumor drugs that had low MICs. indicate that the slope of the standard curve (zone size versus drug concentration) increased more rapidly with the antitumor drugs than with the other antimicrobial drugs. This suggests that, at concentrations of antibiotics less than those of the drug intersect points for the antitumor-antimicrobial drugs, the presence of selected antineoplastic agents may interfere with the determination of antimicrobial concentration by bioassay. Conversely with staphylococcal assay systems (Fig. 1E-F Figure 1C shows that even low concentrations of 5-fluorouracil produce zone sizes so large that the assay of cephalothin in this system would be impractical at concentrations of less than 40 ,ug/ ml and may be difficult at any concentration. This type of experiment was also performed with 5-fluorouracil by the C. perfringens and Klebsiella assays, and with dactinomycin by the Staphylococcus, Bacillus, and Klebsiella assays.
Instances where no zones of inhibition occurred when drug concentrations were as high as 80 ,ug/ml showed a lack of congruity between broth MICs, which suggested moderate susceptibility of Klebsiella to both 5-fluorouracil and dactinomycin as well as susceptibility of Clostridium and Staphylococcus to 5-fluorouracil, and which also suggested low levels of susceptibility by disk diffusion techniques. These results led us to determine the effect of the medium on the disk diffusion procedure in the Klebsiella and Sarcina assay systems (Table 3 ). These data suggest that pH has little or no effect on the expected activity of the antineoplastic agents tested, whereas media may have a marked effect resulting in a reduction of bacterial growth inhibition in the presence of some antineoplastic agents. 
DISCUSSION
The importance of monitoring antimicrobial levels in patients receiving certain antibiotics is well established (2) . Such procedures are beneficial to patients by insuring adequate antibacterial therapy while limiting risks due to the accumulation of compounds to toxic levels. Among patients who frequently receive extensive, and therefore potentially toxic, antimicrobial therapy are those who derive their infections secondary to. neoplastic presence and antineoplastic therapy. Antineoplastic therapy often reduces host antimicrobial defenses to a point of considerable vulnerability to serious infections. Although recent reports have shown that some antibacterial benefits may be derived from the use of certain tumor chemotherapeutic agents (1, 3) , no one, to our knowledge, has investigated the effect that these agents may have on bioassays of concomitantly administered antibiotics.
The selection of antitumor agents used in this study was based on the extent of their use within our institution. The mechanisms of action of these drugs are representative of those of antitumor drugs in general with two notable excep- (Table 4 ). The therapeutic antimicrobial agents actually used in this study are representative of several classes of antimicrobial compounds that might be assayed by the procedures employed. We selected those antimicrobial drugs which are most commonly used and therefore seemed to have the greatest practicality associated with the study.
The data reported here suggest that some caution should be exercised when performing antimicrobial bioassays on sera of patients receiving antitumor therapy. This is particularly true for patients receiving 5-fluorouracil as it has a fairly low MIC for several of the assay organisms and also reaches blood levels as high as 40 ,ug/ml (10) . It is also possible that under some circumstances both dactinomycin and doxorubicin could be present in the blood in concentrations sufficient to interfere with assay of some antibiotics (Fig. 1) . This is particularly true with respect to the assay of carbenicillin or other drugs requiring use of staphylococci, C. perfringens, or S. lutea in the assay system. The data in Table 2 suggest that for patients receiving dactinomycin, the Klebsiella assay system would likely be most useful.
The level at which these antitumor drugs are expected to appear in patient sera is not entirely clear. However, in general, it is expected that 10 ,ug/ml would be unusual; yet much higher levels of methotrexate and 5-fluorouracil might be expected. The relatively low MIC of doxorubicin for S. leutea and C. perfringens was not carried over into the assay systems, and, except for unusual circumstances, this drug should not interfere with bioassay using these bacteria.
The fact that Klebsiella was inhibited by 5-fluorouracil when assayed on Mueller-Hinton but not on antibiotic no. 11 agar (Table 3) suggests that the use of the recommended assay media seems most appropriate. There appears to be either an inactivation of the drug by the components of some media or a reversal of the antimetabolite effect due to the nutrient content of the medium involved. Additional study suggested that pH inactivation of the drug was not a factor on growth over the pH range studied.
Vinblastine, methotrexate, and cytarabine were found to have very high MICs and did not interfere with the various disk bioassay systems. In light of the report by Jacobs et al. (3) that synergy and antagonism between antitumor and antibacterial drugs were observed, it was somewhat surprising that neither activity was observed in our study for any drug combination at any concentration tested. However, the drug concentrations used in their study were as much as 10 times those used by us. We feel that the value of further study of possible interactions at much higher drug levels is not indicated because of the low blood level concentrations of antitumor agents obtained in normal use.
Further study of possible chemotherapeutic antibiotic interaction seems to be suggested either as new agents are developed for therapy or as alternative assay systems are developed and applied in the clinical laboratory.
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